Plexxikon's PLX3397 selected for I-SPY 2 breast cancer trial
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo subsidiary Plexxikon's oral small molecule PLX3397 joined the ranks of Amgen's trebananib and ganitumab as well as ganetespib from Synta Pharmaceuticals in the large, multi-arm, investigator-sponsored breast cancer clinical trial known as I-SPY 2.